Full-Time

Director QA for QC

Intellia Therapeutics

Intellia Therapeutics

501-1,000 employees

CRISPR-Cas9 genome-editing therapeutics developer

Compensation Overview

$213.1k - $260.4k/yr

+ Performance-based annual cash bonus + New hire equity grant + Annual equity awards

Cambridge, MA, USA

Hybrid

Hybrid role with expected on-site attendance; employees are expected to meet the required time on site.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Minitab
Quality Assurance (QA)
Data Analysis

Get referred to Intellia Therapeutics

See people who can refer or advise you

Requirements
  • Prior experience with direct or indirect oversight of employees.
  • Knowledge of the use and interpretation of FDA and International Council for Harmonisation regulatory guidelines and pharmacopeias such as USP/NF, EP, and JP.
  • Knowledge and experience with electronic systems such as EDMS and LIMS.
  • Prior experience with stability requirements in the pharmaceutical industry and generation of in-house reference standards.
  • Experience with data analysis software such as JMP, Minitab, GraphPad Prism, and PLA.
  • Technical understanding of analytical techniques, including HPLC/UPLC, CE, compendial methods, UV, bioassay, and gel electrophoresis.
  • Advanced degree in Chemistry, Molecular/Cell Biology, Pharmaceutical Sciences, Biotechnology, Engineering, or a related scientific discipline; MS/PhD preferred.
  • 10-12 years of relevant industry experience.
  • Experience in phase-appropriate GMP testing and laboratory operations for cell and gene therapies or biologics.
  • Expertise in qualification, validation, transfer, and lifecycle management of analytical methods.
  • Experience with health authority inspections, related observations, and implementation of CAPAs.
  • Experience with IND or BLA filings for ATMP or biologic products.
  • Experience with commercial QC activities.
  • Ability to manage and prioritize multiple projects and consistently meet deadlines.
  • Ability to collaborate effectively in a cross-functional matrix environment and lead with curiosity and influence across functional and organizational lines.
Responsibilities
  • Provide quality and technical oversight and governance for all QC activities, including drug substance and drug product release, stability, and specialized testing for gene editing therapies.
  • Ensure outsourced testing operations comply with applicable global regulations and internal Quality standards for novel modality products.
  • Act as the primary Quality escalation point for critical QC-related quality and compliance issues.
  • Establish and lead a data-driven trending program using stability, release, and routine testing data to identify shifts in analytical, process, or product performance.
  • Partner with Analytical Development, Process Development, and Manufacturing Sciences to develop statistically sound approaches to specification setting, control limits, and continued process verification.
  • Use statistical tools, control charting, and multivariate trend analysis to detect variability and inform proactive risk mitigation.
  • Integrate trend outputs into Quality Risk Management pathways.
  • Provide quality oversight and approval of external laboratory investigations, including OOS, OOT, atypical results, deviations, and data integrity events, and ensure effective CAPAs through closure.
  • Support lifecycle management for reference standards and critical reagents unique to gene editing platforms.
  • Support lifecycle management of the stability program, including protocol design input and approval, execution oversight, data review and interpretation, trend analysis, and reporting.
  • Oversee specification management for drug substance and drug product.
  • Provide Quality and technical oversight of analytical method validation, verification, lifecycle management, and method transfers.
  • Partner with Regulatory Affairs on specification-related regulatory submissions, variations, and pre-commercial regulatory interactions.
  • Lead or support QA audits and regulatory inspections of QC laboratories and ensure findings and commitments are addressed and sustained.
  • Drive continuous improvement initiatives across QC processes, analytical efficiency, and compliance maturity.
  • Contribute QC metrics, trends, and risk assessments to Quality Management Review and other forums.
  • Support selection, qualification, and ongoing oversight of external QC laboratories and CMOs.
  • Recruit, interview, hire, and train new QA for QC staff.
  • Oversee the daily workflow of the department.
  • Provide performance evaluations and handle employee discipline and termination in accordance with company policy.
  • Manage employee workloads and ensure assignments are completed on time.
  • Manage expectations for remote and hybrid employee role designations and required on-site attendance.
Desired Qualifications
  • Serve as a technical mentor and coach to QC and QA personnel, building capability for commercial GMP operations.
  • Provide functional leadership, mentoring, and development for QA staff supporting QC oversight.
  • Support team maturation during the company’s transformation into a clinical and commercial organization.
  • Strong leadership qualities, including strategic thinking, innovation, mentoring, and collaboration.
  • Experience with FDA and ICH guidelines and pharmacopeias such as USP/NF, EP, and JP.
  • Experience with data analysis software such as JMP, Minitab, GraphPad Prism, and PLA.
Intellia Therapeutics

Intellia Therapeutics

View

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Get referred to Intellia Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Intellia ended Q2 2026 with $628.4 million, funding operations at least into 2028.
  • The April 2026 equity raise added $195 million and de-risked launch spending.
  • Positive Phase 3 data and rolling BLA submission position lonvo-z for first-mover revenue.

What critics are saying

  • Approval still hinges on FDA action by March 10, 2027; a CRL stalls commercialization.
  • Q2 2026 collaboration revenue fell to $7.7 million, exposing dependence on Regeneron economics.
  • Commercial launch execution in 2027 requires manufacturing, reimbursement, and safety monitoring under intense scrutiny.

What makes Intellia Therapeutics unique

  • Intellia’s lonvo-z became the first in vivo CRISPR therapy with FDA priority review, September 2026.
  • Its exclusive CRISPR-Cas9 IP and Regeneron partnership support a deep, validated genome-editing platform.
  • HAELO’s 87% attack reduction and 62% attack-free rate separate Intellia from symptom-control drugs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Family Planning Benefits

Fertility Treatment Support

Parenting Leave

Adoption Assistance

Childcare Support

Elder Care Support

Commuter Benefits

Meal Benefits

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

-1%
MarketScreener
Sep 4th, 2026
Intellia Therapeutics, Inc. secures non-dilutive debt facility with OrbiMed for up to $400 million.

Intellia Therapeutics, Inc. secures non-dilutive debt facility with OrbiMed for up to $400 million. Published on 09/04/2026 at 12:06 pm EDT S&P Capital IQ Intellia Therapeutics, Inc. announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm. The facility includes an initial term loan of $75 million that was funded at closing; 5 additional tranches totaling up to $225 million that can be drawn at Intellia?s option subject to its achievement of specified milestones related primarily to lonvo-z; and an additional $100 million available subject to mutual agreement between the parties during the five-year term of the agreement. Additional details of the loan agreement will be filed with the Securities and Exchange Commission on a Current Report on Form 8-K. TD Cowen acted as exclusive financial advisor to Intellia on the transaction. Goodwin Procter LLP acted as legal advisor to Intellia. Covington & Burling LLP acted as legal advisor to OrbiMed. (C) S&P Capital IQ - 2026

MarketScreener
Sep 4th, 2026
Intellia Therapeutics secures $400M non-dilutive debt facility from OrbiMed for HAE treatment launch

Intellia Therapeutics has secured a $400 million non-dilutive senior secured term loan facility with OrbiMed. The deal includes an initial $75 million funded at closing, with up to $225 million available in additional tranches subject to achieving milestones related to lonvoguran ziclumeran (lonvo-z), its treatment for hereditary angioedema. Another $100 million may be available by mutual agreement during the five-year term. The financing provides Intellia with financial flexibility as it prepares for a planned US approval and commercial launch of lonvo-z. "This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts," said Edward Dulac, Intellia's chief financial officer. TD Cowen acted as exclusive financial adviser to Intellia on the transaction.

BioSpace
Jul 22nd, 2026
6 companies hiring in Cambridge now.

6 companies hiring in Cambridge now. July 22, 2026 | Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year. Life sciences professionals looking for employment in Cambridge, Massachusetts, may find more opportunities in that part of the Genetown Hotbed now than they did a year ago. Job postings live on the BioSpace website for Cambridge jumped 120% year over year. They started trending up in February, with only a slight dip in May before rising again last month. If you're interested in working at a pharma or biotech in Cambridge, check out the open positions at these six companies. * Intellia Therapeutics has around 40 jobs available. Roles include vice president, gene editing core; senior director, quality management systems and compliance; and manager, commercial systems. * Regeneron has about a dozen openings. Jobs include scientist-analytical development, Regeneron cell medicines; senior toxicologist; and senior manager clinical study lead (clinical experimental sciences). * Sanofi has over 100 roles available. Positions include senior associate scientist; clinical research director; and director, commercial transformation. * AbbVie has several openings. Jobs include associate scientist, cellular/molecular biochemistry II; senior scientist II, rheumatology; and senior principal scientist, immune cell depletion discovery group, immunology discovery research. * Amgen also has several positions available. Roles include senior quality engineer; process development senior scientist-pivotal drug product technologies; and device engineering senior engineer. * Moderna has over 50 openings. Jobs include scientist, oncology bioinformatics; manager, biomarker operations; and senior research associate, in vivo pharm. Job market trends, layoffs and career advice to manage your life sciences career Angela Gabriel is content manager, life sciences careers, at BioSpace. She covers the biopharma job market, job trends and career advice, and produces client content. You can reach her at [email protected] and follow her on LinkedIn.

Yahoo Finance
Jun 20th, 2026
Intellia vs. Omeros: Which emerging biotech offers better value in 2026?

Intellia Therapeutics, a clinical-stage biotech focused on CRISPR-based gene editing, reported FY 2025 revenue of $67.7 million, up 17% year-over-year, though it posted a net loss of $412.7 million. The company maintains a conservative debt-to-equity ratio of 0.1x and collaborates with Regeneron Pharmaceuticals on neurological and muscular disease treatments. Omeros, transitioning to commercial stage following FDA approval of Yartemlea for transplant-associated thrombotic microangiopathy in late 2025, reported no FY 2025 revenue but improved its net loss to $3.4 million. The company holds $135.3 million in cash against $226.6 million in debt and has partnered with Novo Nordisk on zaltenibart development. Both companies operate in high-risk biotech sectors with distinct strategies.

Business Insider
Jun 14th, 2026
Intellia Therapeutics presents additional results from Phase 3 HAELO trial.

Intellia Therapeutics presents additional results from Phase 3 HAELO trial. Jun. 14, 2026, 02:35 PM Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, HAE, in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology, EAACI, Annual Congress 2026 in Istanbul, Turkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. Today's presentation and publication also included supplemental demographics, data and analyses, including: A time plot showing that the mean monthly attack rate for patients receiving lonvo-z through the data cutoff was well below the reported rate in prescreening while patients were receiving standard-of-care therapy; Patient-level data demonstrating that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28; An analysis showing that meaningful attack-rate reductions were observed for all evaluated subgroups; A breakdown showing that 20% of the patients who enrolled in HAELO reported having complete disease control as their best response to prior long-term prophylaxis therapies; and A plasma kallikrein time plot showing that protein levels decreased substantially by the first measurement, reached a steady state by week 5 and remained stable through the data cutoff. * Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. * Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Published first on TheFly - the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on NTLA: